Sichuan Kelun-Biotech Reports H1 Revenue Drop, Advances Key Drug Commercialization
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) released its financial results for the first half...
WuXi Biologics Reports 16.1% Revenue Growth in H1 2025, Launches WuXiHigh 2.0 Platform
WuXi Biologics (Cayman) Inc. (HKG: 2269), a leading global Contract Research, Development and Manufacturing Organization...
RemeGen’s RC148 Granted Breakthrough Therapy Designation for NSCLC Treatment
RemeGen Co., Ltd. (SHA: 688331, HKG: 9995), a China-based biotech company, announced that its novel...
Shandong Lukang’s CIGB-814 Starts Phase 1 Trial for Rheumatoid Arthritis Treatment
Shandong Lukang Pharmaceutical Co., Ltd. (SHA: 600789) announced that its CIGB-814 immunomodulator has commenced a...
HutchMed Completes Patient Enrollment for Orpathys and Tagrisso Combination Study
Chinese pharmaceutical company HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced the completion of patient...
Sino Biopharmaceutical Reports 10.7% Revenue Growth and 140.2% Profit Surge in H1 2025
China-based Sino Biopharmaceutical Limited (HKG: 1177) announced its financial results for the first half of 2025....
Kangtai Biological Gains NMPA Approval for Trivalent Influenza Vaccine Clinical Trial
Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601) announced that it has received approval from...
Zhifei Biological’s Adult and Adolescent DTaP Vaccine Gains NMPA Trial Approval
Chongqing Zhifei Biological Co., Ltd. (SHE: 300122), based in China, announced that its Acellular Pertussis,...
RemeGen Inks Licensing Deal With Santen China for RC28-E Eye Disease Drug
China-based RemeGen Co., Ltd. (SHA: 688331, HKG: 9995) announced an agreement with Santen China, a...
MicroPort CardioFlow’s Alwide Plus Wins EU CE Mark for Heart Valve Procedures
China-based MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), based in China, announced that its independently...
Mabwell’s Innovative CDH17-Targeted ADC 7MW4911 Receives FDA Clinical Trial Approval
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced that its self-developed CDH17-targeted antibody-drug conjugate...
Hengrui Pharma’s Hetrombopag Olamine Accepted by NMPA for Chemotherapy-Induced Thrombocytopenia
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced that the National Medical Products...
WuXi XDC Reports Strong H1 2025 Growth With 62.2% Revenue Increase
China-based WuXi XDC Cayman Inc. (HKG: 2268), a leading global Contract Research, Development, and Manufacturing...
Genentech to End $2B Collaboration With Adaptive Biotechnologies on T-Cell Therapies
Genentech, a member of the Roche Group (SWX: ROG, OTCMKTS: RHHBY), will terminate its strategic...
Henlius Partners with GeneQuantum on HER2-Targeted ADC GQ1005 Development
Shanghai Henlius Biotech Inc. (HKG: 2696) announced a strategic collaboration with China-based GeneQuantum Healthcare. The...
Acotec Scientific’s Micro-Guidewire Receives Beijing Medical Products Administration Approval
China-based Acotec Scientific Holdings Limited (HKG: 6669) announced that its micro-guidewire has received registration approval...
Skyhawk Therapeutics Collaborates with Merck on RNA-Targeting Small Molecules for Neurological Diseases
Skyhawk Therapeutics, Inc. announced on August 18, 2025, a strategic research collaboration with Merck KGaA...
Sichuan Biokin’s Iza-Bren Granted FDA Breakthrough Therapy Designation for NSCLC
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced that its bispecific antibody-drug conjugate (ADC), izalontamab...
Ascentage Pharma’s Lisaftoclax Gains FDA and EMA Clearance for Global Phase III Trial
Ascentage Pharma Group International (HKG: 6855) announced that it has received clearance from the U.S....
Novo Nordisk’s Wegovy Granted FDA Approval for Metabolic-Associated Steatohepatitis
Danish biopharmaceutical giant Novo Nordisk A/S (NYSE: NVO) announced on August 15, 2025, that its...